Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD52 | P43351 | 1/20 | 0.87 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.65 |
| ▸ | MAPT | P10636 | 9/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.58 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30401813 | 0.92 | RAD52 (0.74) | RAD52KMT2AMAPTNPC1ALDH1A1 | |
| SCHEMBL25300551 | 0.92 | KMT2A (0.76) | RAD52KMT2AMAPTNPC1ALDH1A1 | |
| SCHEMBL25811302 | 0.92 | RAD52 (0.74) | RAD52KMT2AMAPTNPC1ALDH1A1 | |
| SCHEMBL25811381 | 0.91 | KMT2A (0.78) | RAD52KMT2AMAPTNPC1ALDH1A1 | |
| SCHEMBL25811288 | 0.89 | KMT2A (0.79) | RAD52KMT2AMAPTNPC1ALDH1A1 | |
| SCHEMBL25812546 | 0.88 | RAD52 (0.69) | RAD52KMT2AMAPTNPC1HDAC2 | |
| SCHEMBL25811257 | 0.86 | RAD52 (0.66) | RAD52KMT2AMAPTNPC1ALDH1A1 | |
| SCHEMBL30312306 | 0.86 | RAD52 (0.66) | RAD52KMT2AMAPTNPC1ALDH1A1 | |
| SCHEMBL2161708 | 0.83 | KMT2A (0.74) | RAD52KMT2AMAPTMEN1 | |
| SCHEMBL25811723 | 0.82 | RAD52 (0.61) | RAD52KMT2AMAPTHDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218573-A1 | INDOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | GALYAN BIO INC (US) | 2023-07-13 | — | — | US | disclosed |
| US-20230218573-A1 | INDOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | GALYAN BIO INC (US) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230218573-A1 | INDOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | HTT, HYPK, PARK7 | RAD52 1790/4885KMT2A 981/4885MAPT 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.